Clinical Resistance to CDK4/6 Inhibitors: Why Cyclin E-CDK2 Is the Next Therapeutic Frontier
Trends in Oncology
Daniel Ciznadija, PhD
Director of Research Analytics Champions Oncology, Inc.
Clinical Resistance to CDK4/6 Inhibitors: Why Cyclin E-CDK2 Is the Next Therapeutic Frontier